Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad) Buy MIRM Stock  Free MIRM Stock Alerts

Mirum Pharmaceuticals (MIRM) Financials

Mirum Pharmaceuticals logo
$44.34 +0.34 (+0.77%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$47.71 +3.37 (+7.60%)
As of 05/30/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Mirum Pharmaceuticals

Annual Income Statements for Mirum Pharmaceuticals

This table shows Mirum Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -88 -163 -136 -84 -103 -53
Consolidated Net Income / (Loss)		 -88 -163 -136 -84 -103 -53
Net Income / (Loss) Continuing Operations		 -88 -163 -135 -84 -103 -53
Total Pre-Tax Income 		-87 -162 -142 -84 -103 -53
Total Operating Income		 -88 -109 -131 -173 -104 -55
Total Gross Profit		 255 139 65 19 0.00 0.00
Total Revenue		 337 186 77 19 0.00 0.00
Operating Revenue		 337 186 77 19 0.00 -
Total Cost of Revenue		 82 47 12 0.00 0.00 0.00
Operating Cost of Revenue		 82 47 12 - - -
Total Operating Expenses		 343 248 196 193 104 55
Selling, General & Admin Expense		 202 146 89 59 23 12
Research & Development Expense		 141 103 107 131 82 43
Total Other Income / (Expense), net		 0.69 -53 -11 89 1.03 2.21
Interest Expense		 14 64 16 18 0.34 0.00
Interest & Investment Income		 14 14 3.86 0.37 1.56 2.23
Other Income / (Expense), net		 1.21 -2.82 0.91 107 -0.19 -0.02
Income Tax Expense		 1.03 0.99 -6.41 0.04 0.01 0.02
Basic Earnings per Share		 ($1.85) ($4.00) ($4.01) ($2.77) ($4.09) ($4.58)
Weighted Average Basic Shares Outstanding		 47.52M 40.89M 33.84M 30.32M 25.25M 11.49M
Diluted Earnings per Share		 ($1.85) ($4.00) ($4.02) ($2.77) ($4.09) ($4.58)
Weighted Average Diluted Shares Outstanding		 47.52M 40.89M 33.98M 30.32M 25.25M 11.49M
Weighted Average Basic & Diluted Shares Outstanding		 49.01M 47.00M 37.95M 30.32M 25.25M 11.49M

Quarterly Income Statements for Mirum Pharmaceuticals

This table shows Mirum Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -15 -24 -14 -25 -25 -36 -24 -74 -30 -36 -36
Consolidated Net Income / (Loss)		 -15 -24 -14 -25 -25 -36 -24 -74 -30 -36 -36
Net Income / (Loss) Continuing Operations		 -15 -24 -14 -25 -25 -36 -24 -74 -30 -36 -36
Total Pre-Tax Income 		-14 -24 -14 -24 -25 -35 -23 -74 -30 -36 -36
Total Operating Income		 -15 -24 -13 -24 -26 -33 -25 -24 -27 -34 -33
Total Gross Profit		 89 77 70 58 51 45 37 31 27 16 19
Total Revenue		 112 99 90 78 69 70 48 37 32 28 19
Operating Revenue		 112 99 90 78 69 70 48 37 32 28 19
Total Cost of Revenue		 23 23 21 20 18 25 10 6.81 4.98 12 0.00
Operating Cost of Revenue		 23 23 21 20 18 25 10 6.81 4.98 - -
Total Operating Expenses		 104 101 82 82 78 77 63 55 54 50 52
Selling, General & Admin Expense		 58 57 51 49 46 46 37 33 30 26 23
Research & Development Expense		 46 44 32 33 32 31 26 22 24 31 26
Total Other Income / (Expense), net		 1.54 -0.14 -1.20 0.23 1.81 -2.85 1.81 -49 -2.78 -2.50 -2.81
Interest Expense		 3.60 3.58 3.59 3.57 3.58 3.56 3.57 53 4.24 4.36 3.97
Interest & Investment Income		 3.02 3.20 3.47 3.49 3.63 3.78 4.06 3.63 2.27 2.14 1.35
Other Income / (Expense), net		 2.11 0.23 -1.09 0.31 1.76 -3.06 1.32 -0.27 -0.81 -0.28 -0.19
Income Tax Expense		 1.03 -0.58 0.35 0.64 0.62 0.23 0.25 0.32 0.20 0.14 0.01
Basic Earnings per Share		 ($0.30) ($0.49) ($0.30) ($0.52) ($0.54) ($0.69) ($0.57) ($1.94) ($0.80) ($0.98) ($1.02)
Weighted Average Basic Shares Outstanding		 48.89M 47.52M 47.78M 47.24M 46.93M 40.89M 41.10M 38.11M 37.68M 33.84M 34.93M
Diluted Earnings per Share		 ($0.30) ($0.49) ($0.30) ($0.52) ($0.54) ($0.69) ($0.57) ($1.94) ($0.80) ($0.99) ($1.02)
Weighted Average Diluted Shares Outstanding		 48.89M 47.52M 47.78M 47.24M 46.93M 40.89M 41.10M 38.11M 37.68M 33.98M 34.93M
Weighted Average Basic & Diluted Shares Outstanding		 49.53M 49.01M 48.00M 47.71M 47.13M 47.00M 46.61M 38.30M 38.03M 37.95M 36.87M

Annual Cash Flow Statements for Mirum Pharmaceuticals

This table details how cash moves in and out of Mirum Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Change in Cash & Equivalents		 -63 158 -3.34 -11 130 -40
Net Cash From Operating Activities		 10 -71 -120 -133 -89 -39
Net Cash From Continuing Operating Activities		 10 -71 -120 -133 -87 -39
Net Income / (Loss) Continuing Operations		 -88 -163 -136 -84 -103 -53
Consolidated Net Income / (Loss)		 -88 -163 -136 -84 -103 -53
Depreciation Expense		 24 11 3.24 0.60 0.31 0.14
Amortization Expense		 1.66 1.12 0.00 -0.14 0.25 -0.14
Non-Cash Adjustments To Reconcile Net Income		 50 100 40 -66 13 5.99
Changes in Operating Assets and Liabilities, net		 23 -19 -28 17 2.43 7.21
Net Cash From Investing Activities		 -90 -107 7.70 49 38 -128
Net Cash From Continuing Investing Activities		 -90 -107 7.70 49 38 -128
Purchase of Property, Plant & Equipment		 -0.99 -0.11 -0.28 -0.02 -0.23 -0.28
Acquisitions		 -20 -233 0.00 -19 - -
Purchase of Investments		 -89 -27 -132 -198 -75 -152
Sale and/or Maturity of Investments		 20 153 140 158 113 25
Net Cash From Financing Activities		 18 337 109 73 181 127
Net Cash From Continuing Financing Activities		 18 337 109 73 181 127
Repurchase of Common Equity		 0.00 -0.28 0.00 0.00 - 0.00
Issuance of Debt		 0.00 305 0.00 0.00 - -
Issuance of Common Equity		 18 227 115 9.01 132 67
Other Financing Activities, net		 0.00 -196 -5.55 64 50 0.00
Effect of Exchange Rate Changes		 -1.30 -0.13 0.01 -0.00 0.03 -
Cash Interest Paid		 13 6.82 0.00 0.00 - -
Cash Income Taxes Paid		 1.00 0.13 0.00 0.00 0.01 0.02

Quarterly Cash Flow Statements for Mirum Pharmaceuticals

This table details how cash moves in and out of Mirum Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -11 -0.47 -10 -69 17 -17 5.83 148 21 -7.76 -20
Net Cash From Operating Activities		 -1.96 -5.07 3.98 -3.80 15 -17 -18 -17 -19 -34 -26
Net Cash From Continuing Operating Activities		 -1.96 -5.07 3.98 -3.80 15 -17 -18 -17 -19 -34 -26
Net Income / (Loss) Continuing Operations		 -15 -24 -14 -25 -25 -36 -24 -74 -30 -36 -36
Consolidated Net Income / (Loss)		 -15 -24 -14 -25 -25 -36 -24 -74 -30 -36 -36
Depreciation Expense		 6.05 6.06 6.06 5.85 5.66 5.49 2.66 1.34 1.34 1.20 1.10
Amortization Expense		 0.43 0.42 0.42 0.41 0.41 0.40 0.41 0.31 0.00 0.69 -0.58
Non-Cash Adjustments To Reconcile Net Income		 18 14 8.41 15 13 21 7.94 59 13 9.23 11
Changes in Operating Assets and Liabilities, net		 -11 -1.68 3.33 -0.79 22 -7.45 -5.64 -3.50 -2.63 -8.96 -1.82
Net Cash From Investing Activities		 -16 0.64 -18 -73 -0.01 -2.00 -183 51 27 27 -80
Net Cash From Continuing Investing Activities		 -16 0.64 -18 -73 -0.01 -2.00 -183 51 27 27 -80
Purchase of Property, Plant & Equipment		 -0.04 -0.02 -0.18 -0.78 -0.01 - - -0.07 -0.04 -0.24 -0.02
Purchase of Investments		 -34 -11 -16 -62 0.00 - - -4.89 -22 - -118
Sale and/or Maturity of Investments		 17 12 7.75 - 0.00 3.00 30 56 65 27 38
Net Cash From Financing Activities		 6.36 5.34 3.86 7.29 1.21 1.78 207 115 13 -0.33 86
Net Cash From Continuing Financing Activities		 6.36 5.34 3.86 7.29 1.21 1.78 207 115 13 -0.33 86
Issuance of Common Equity		 6.36 5.34 3.86 7.29 1.21 2.06 207 2.10 16 1.70 88
Effect of Exchange Rate Changes		 1.06 -1.38 0.09 -0.12 0.11 0.11 -0.32 -0.11 0.19 0.09 -0.02
Cash Income Taxes Paid		 0.16 0.23 0.43 0.20 0.14 0.13 - - 0.00 - -

Annual Balance Sheets for Mirum Pharmaceuticals

This table presents Mirum Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Total Assets		 671 647 353 295 241 147 52
Total Current Assets		 393 388 190 167 236 119 52
Cash & Equivalents		 223 286 28 31 142 12 52
Restricted Cash		 0.43 0.00 - - - - -
Short-Term Investments		 58 0.00 124 125 90 105 0.00
Accounts Receivable		 78 68 24 3.27 0.00 - -
Inventories, net		 22 22 5.57 1.51 0.00 - -
Prepaid Expenses		 12 11 8.95 5.27 4.53 2.70 0.01
Plant, Property, & Equipment, net		 1.14 0.71 0.91 0.98 1.29 1.37 0.00
Total Noncurrent Assets		 276 258 162 127 3.22 26 0.00
Long-Term Investments		 13 0.00 - 4.98 0.00 23 0.00
Intangible Assets		 250 253 59 19 0.00 - -
Other Noncurrent Operating Assets		 14 5.45 103 103 3.22 2.69 0.00
Total Liabilities & Shareholders' Equity		 671 647 353 295 241 147 52
Total Liabilities		 445 398 211 174 69 16 2.45
Total Current Liabilities		 127 87 65 43 18 13 2.45
Accounts Payable		 15 7.42 8.69 9.17 3.15 3.35 0.27
Accrued Expenses		 110 79 54 31 13 9.33 2.18
Other Current Liabilities		 1.71 1.10 2.02 2.71 1.90 0.40 0.00
Total Noncurrent Liabilities		 319 311 146 132 50 3.29 0.00
Long-Term Debt		 308 306 0.00 - - - -
Other Noncurrent Operating Liabilities		 10 4.47 146 132 50 3.29 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 226 249 142 120 172 130 -17
Total Preferred & Common Equity		 226 249 142 120 172 130 -17
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 226 249 142 120 172 130 -17
Common Stock		 870 803 535 377 345 200 0.04
Retained Earnings		 -644 -556 -393 -257 -173 -70 -17
Accumulated Other Comprehensive Income / (Loss)		 -0.37 1.64 -0.22 -0.04 0.08 0.13 0.00

Quarterly Balance Sheets for Mirum Pharmaceuticals

This table presents Mirum Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 690 668 661 652 651 444 334 364
Total Current Assets		 411 387 368 389 389 384 172 216
Cash & Equivalents		 212 223 233 303 303 297 49 36
Restricted Cash		 0.43 0.43 0.25 - 0.00 - - -
Short-Term Investments		 66 61 45 - 2.97 33 83 150
Accounts Receivable		 96 69 60 55 48 35 25 16
Inventories, net		 22 22 20 22 22 8.51 6.61 6.94
Prepaid Expenses		 15 12 8.59 10 12 9.73 8.99 6.93
Plant, Property, & Equipment, net		 1.11 1.21 1.10 0.50 0.79 0.87 0.88 0.80
Total Noncurrent Assets		 278 280 292 262 261 59 160 148
Long-Term Investments		 21 9.32 17 - - - - 0.00
Intangible Assets		 244 256 262 257 258 56 58 45
Other Noncurrent Operating Assets		 13 15 13 4.55 2.94 2.77 103 103
Total Liabilities & Shareholders' Equity		 690 668 661 652 651 444 334 364
Total Liabilities		 457 436 432 417 382 365 192 195
Total Current Liabilities		 128 116 112 106 75 58 49 51
Accounts Payable		 12 9.55 9.84 16 7.37 14 6.44 11
Accrued Expenses		 116 105 101 90 66 43 40 38
Total Noncurrent Liabilities		 329 320 319 311 307 307 144 144
Long-Term Debt		 309 308 307 307 306 306 - -
Other Noncurrent Operating Liabilities		 21 12 12 4.62 0.88 1.16 144 144
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 233 232 229 235 269 79 141 169
Total Preferred & Common Equity		 233 232 229 235 269 79 141 169
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 233 232 229 235 269 79 141 169
Common Stock		 892 851 836 816 791 576 564 526
Retained Earnings		 -659 -620 -606 -582 -521 -497 -423 -356
Accumulated Other Comprehensive Income / (Loss)		 -0.26 0.92 -0.48 -0.01 -1.46 0.08 0.14 -0.41

Annual Metrics And Ratios for Mirum Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Mirum Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Growth Metrics		 - - - - - -
Revenue Growth		 80.76% 141.85% 302.66% 0.00% 0.00% 0.00%
EBITDA Growth		 38.92% 21.28% -91.76% 36.24% -89.78% 0.00%
EBIT Growth		 22.85% 14.07% -95.29% 36.14% -90.80% 0.00%
NOPAT Growth		 19.74% 16.82% 24.33% -66.27% -90.52% 0.00%
Net Income Growth		 46.18% -20.45% -61.53% 18.67% -96.51% 0.00%
EPS Growth		 53.75% 0.50% -45.13% 32.27% 10.70% 0.00%
Operating Cash Flow Growth		 114.55% 40.95% 9.51% -49.04% -126.30% 0.00%
Free Cash Flow Firm Growth		 90.70% -187.37% 11.67% -510.88% 0.00% 0.00%
Invested Capital Growth		 -10.53% 2,875.92% 76.56% 30.83% -521.94% 0.00%
Revenue Q/Q Growth		 9.73% 28.78% 47.36% 19.61% 0.00% 0.00%
EBITDA Q/Q Growth		 18.60% 3.97% -282.02% 59.72% -21.35% 0.00%
EBIT Q/Q Growth		 11.89% -1.42% -276.47% 59.56% -21.31% 0.00%
NOPAT Q/Q Growth		 8.71% 1.42% 8.00% -5.23% -21.27% 0.00%
Net Income Q/Q Growth		 11.89% 0.47% -225.43% 53.01% -22.91% 0.00%
EPS Q/Q Growth		 9.76% 6.98% -258.93% 54.74% -417.05% 0.00%
Operating Cash Flow Q/Q Growth		 942.86% 19.92% -0.94% 2.30% -33.96% 0.00%
Free Cash Flow Firm Q/Q Growth		 24.28% 2.15% 46.87% -806.47% 0.00% 0.00%
Invested Capital Q/Q Growth		 -2.05% -0.11% 39.68% 72.21% -342.60% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 75.77% 74.76% 83.94% 100.00% 0.00% 0.00%
EBITDA Margin		 -18.14% -53.67% -164.90% -346.27% 0.00% 0.00%
Operating Margin		 -26.00% -58.57% -170.28% -906.12% 0.00% 0.00%
EBIT Margin		 -25.64% -60.08% -169.10% -348.66% 0.00% 0.00%
Profit (Net Income) Margin		 -26.10% -87.68% -176.05% -438.85% 0.00% 0.00%
Tax Burden Percent		 101.19% 100.61% 95.49% 100.04% 100.01% 100.04%
Interest Burden Percent		 100.60% 145.05% 109.02% 125.81% 98.83% 95.92%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -24.09% -58.98% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -176.58% 73.22% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -13.00% -24.67% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -37.08% -83.65% -103.46% -57.47% -68.29% -58.43%
Cash Return on Invested Capital (CROIC)		 -12.97% -132.03% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -13.12% -22.41% -40.25% -24.92% 0.00% 0.00%
Return on Assets (ROA)		 -13.35% -32.70% -41.90% -31.37% 0.00% 0.00%
Return on Common Equity (ROCE)		 -37.08% -83.65% -103.46% -57.47% -68.29% -36.72%
Return on Equity Simple (ROE_SIMPLE)		 -38.97% -65.72% -95.51% -69.87% -60.01% -40.32%
Net Operating Profit after Tax (NOPAT)		 -61 -76 -92 -121 -73 -38
NOPAT Margin		 -18.20% -41.00% -119.19% -634.28% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 152.49% -132.21% -27.97% 19.02% -16.28% -10.17%
Return On Investment Capital (ROIC_SIMPLE)		 -11.49% -13.76% -64.67% - - -
Cost of Revenue to Revenue		 24.23% 25.24% 16.06% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 60.03% 78.27% 115.58% 309.44% 0.00% 0.00%
R&D to Revenue		 41.74% 55.06% 138.64% 686.74% 0.00% 0.00%
Operating Expenses to Revenue		 101.77% 133.33% 254.22% 1,006.12% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -86 -112 -130 -67 -104 -55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -100 -127 -66 -104 -55
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 8.80 5.53 5.06 4.07 2.61 4.32
Price to Tangible Book Value (P/TBV)		 0.00 0.00 8.65 4.82 2.61 4.32
Price to Revenue (P/Rev)		 5.89 7.38 9.33 25.53 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 8.32 5.19 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5.94 7.49 7.36 17.09 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 193.69 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 1.37 1.23 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 1.37 1.23 0.00 0.00 0.00 0.00
Financial Leverage		 0.07 -0.34 -1.19 -1.35 -1.23 -1.07
Leverage Ratio		 2.78 2.56 2.47 1.83 1.28 1.10
Compound Leverage Factor		 2.79 3.71 2.69 2.30 1.27 1.06
Debt to Total Capital		 57.72% 55.20% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 57.72% 55.20% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 42.28% 44.80% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -5.04 -3.06 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.24 -0.20 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -5.04 -3.06 0.00 0.00 0.00 0.00
Debt to NOPAT		 -5.02 -4.01 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -0.24 -0.26 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -5.02 -4.01 0.00 0.00 0.00 0.00
Altman Z-Score		 1.88 1.14 -0.09 0.28 2.57 19.64
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 37.16%
Liquidity Ratios		 - - - - - -
Current Ratio		 3.10 4.45 2.94 3.91 12.80 9.13
Quick Ratio		 2.83 4.07 2.71 3.75 12.56 8.92
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 -33 -355 -123 -140 -23 0.00
Operating Cash Flow to CapEx		 1,039.78% -65,086.24% -43,214.39% -553,158.33% -39,588.89% -14,007.83%
Free Cash Flow to Firm to Interest Expense		 -2.31 -5.53 -7.73 -7.95 -68.31 0.00
Operating Cash Flow to Interest Expense		 0.72 -1.11 -7.52 -7.55 -265.90 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.65 -1.11 -7.54 -7.55 -266.57 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.51 0.37 0.24 0.07 0.00 0.00
Accounts Receivable Turnover		 4.61 4.05 5.65 0.00 0.00 0.00
Inventory Turnover		 3.65 3.37 3.50 0.00 0.00 0.00
Fixed Asset Turnover		 365.19 230.09 81.33 16.83 0.00 0.00
Accounts Payable Turnover		 7.41 5.84 1.39 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 79.23 90.05 64.56 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 99.95 108.16 104.39 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 49.25 62.49 263.35 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 129.93 135.72 -94.40 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 240 269 -9.68 -41 -60 -9.60
Invested Capital Turnover		 1.32 1.44 -3.02 -0.38 0.00 0.00
Increase / (Decrease) in Invested Capital		 -28 278 32 18 -50 0.00
Enterprise Value (EV)		 2,000 1,396 567 327 217 424
Market Capitalization		 1,985 1,376 719 489 449 564
Book Value per Share		 $4.70 $5.33 $3.85 $3.92 $6.69 $5.67
Tangible Book Value per Share		 ($0.50) ($0.09) $2.25 $3.31 $6.69 $5.67
Total Capital		 534 555 142 120 172 130
Total Debt		 308 306 0.00 0.00 0.00 0.00
Total Long-Term Debt		 308 306 0.00 0.00 0.00 0.00
Net Debt		 15 20 -152 -162 -232 -140
Capital Expenditures (CapEx)		 0.99 0.11 0.28 0.02 0.23 0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 14 -26 -33 -14 -10
Debt-free Net Working Capital (DFNWC)		 266 300 125 124 218 106
Net Working Capital (NWC)		 266 300 125 124 218 106
Net Nonoperating Expense (NNE)		 27 87 44 -37 30 14
Net Nonoperating Obligations (NNO)		 15 20 -152 -162 -232 -140
Total Depreciation and Amortization (D&A)		 25 12 3.24 0.46 0.55 -0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -4.31% 7.59% -34.03% -170.05% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 79.03% 161.22% 162.85% 647.90% 0.00% 0.00%
Net Working Capital to Revenue		 79.03% 161.22% 162.85% 647.90% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 ($1.85) ($4.00) ($4.01) ($2.77) ($4.09) ($4.58)
Adjusted Weighted Average Basic Shares Outstanding		 47.52M 40.89M 33.84M 31.73M 30.42M 25.39M
Adjusted Diluted Earnings per Share		 ($1.85) ($4.00) ($4.02) ($2.77) ($4.09) ($4.58)
Adjusted Weighted Average Diluted Shares Outstanding		 47.52M 40.89M 33.98M 31.73M 30.42M 25.39M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.77) ($4.09) ($4.58)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.01M 47.00M 37.95M 30.32M 25.25M 11.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -61 -76 -92 -121 -73 -38
Normalized NOPAT Margin		 -18.20% -41.00% -119.19% -634.28% 0.00% 0.00%
Pre Tax Income Margin		 -25.80% -87.15% -184.36% -438.66% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -6.04 -1.74 -8.16 -3.79 -311.90 0.00
NOPAT to Interest Expense		 -4.29 -1.19 -5.75 -6.90 -217.93 0.00
EBIT Less CapEx to Interest Expense		 -6.11 -1.75 -8.17 -3.79 -312.58 0.00
NOPAT Less CapEx to Interest Expense		 -4.35 -1.19 -5.77 -6.90 -218.60 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.17% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Mirum Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Mirum Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 61.20% 42.93% 89.37% 107.68% 119.07% 149.24% 154.13% 114.46% 145.10% 789.29% 275.60%
EBITDA Growth		 64.63% 41.12% 64.86% 22.90% 30.01% 8.60% 36.26% 22.28% 18.07% -153.14% 21.32%
EBIT Growth		 47.09% 32.70% 42.20% 2.55% 11.62% -3.50% 27.96% 17.93% 14.99% -156.22% 20.31%
NOPAT Growth		 42.64% 25.67% 49.56% 0.17% 2.50% 4.61% 23.52% 22.80% 17.07% 47.52% 23.22%
Net Income Growth		 41.94% 33.28% 39.65% 66.72% 16.10% 2.12% 33.94% -175.01% 17.69% -163.31% 24.20%
EPS Growth		 44.44% 28.99% 47.37% 73.20% 32.50% 30.30% 44.12% -130.95% 31.62% -151.83% 34.19%
Operating Cash Flow Growth		 -112.89% 69.50% 121.86% 78.06% 181.03% 51.51% 29.99% 14.08% 52.67% -3.39% 23.91%
Free Cash Flow Firm Growth		 94.04% 103.77% 104.85% -137.63% -320.01% -442.39% -94.55% 43.30% 17.02% 13.19% -247.96%
Invested Capital Growth		 1.74% -10.53% -8.76% 343.24% 2,528.57% 2,875.92% 1,776.47% 480.39% 129.30% 76.56% 89.20%
Revenue Q/Q Growth		 12.24% 10.00% 16.05% 12.50% -0.48% 45.74% 27.28% 18.67% 13.23% 48.59% 7.41%
EBITDA Q/Q Growth		 62.38% -140.25% 58.71% 5.23% 37.44% -43.37% 9.39% 13.97% 21.45% 0.02% -10.49%
EBIT Q/Q Growth		 45.50% -74.21% 42.43% 3.20% 30.68% -49.61% 2.94% 12.20% 17.95% -4.13% -10.58%
NOPAT Q/Q Growth		 37.32% -90.97% 47.66% 8.45% 18.77% -29.57% -3.60% 10.59% 20.53% -3.89% -4.58%
Net Income Q/Q Growth		 38.31% -67.12% 42.22% 2.54% 29.11% -51.17% 68.14% -145.73% 17.30% -2.03% -32.63%
EPS Q/Q Growth		 38.78% -63.33% 42.31% 3.70% 21.74% -21.05% 70.62% -142.50% 19.19% 2.94% -21.43%
Operating Cash Flow Q/Q Growth		 61.31% -227.21% 204.76% -125.00% 191.54% 8.80% -5.14% 7.69% 45.22% -31.68% -29.02%
Free Cash Flow Firm Q/Q Growth		 -230.24% -22.74% 107.23% 18.07% 17.66% 0.49% -253.97% -44.82% -6.33% 64.30% -3.15%
Invested Capital Q/Q Growth		 0.96% -2.05% 2.06% 0.81% -11.23% -0.11% 395.83% 497.85% 193.75% 39.68% -12.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 79.37% 77.09% 76.98% 74.03% 74.24% 64.03% 78.57% 81.83% 84.24% 55.66% 100.00%
EBITDA Margin		 -5.91% -17.62% -8.07% -22.68% -26.92% -42.78% -43.48% -61.08% -84.25% -116.65% -173.38%
Operating Margin		 -13.61% -24.36% -14.03% -31.12% -38.24% -46.85% -52.69% -64.73% -85.92% -122.41% -175.09%
EBIT Margin		 -11.72% -24.13% -15.24% -30.72% -35.70% -51.25% -49.92% -65.46% -88.48% -123.41% -176.11%
Profit (Net Income) Margin		 -13.15% -23.93% -15.75% -31.64% -36.52% -51.27% -49.42% -197.45% -95.35% -130.55% -190.13%
Tax Burden Percent		 107.54% 97.64% 102.50% 102.65% 102.53% 100.64% 101.07% 100.43% 100.67% 100.39% 100.04%
Interest Burden Percent		 104.38% 101.56% 100.85% 100.35% 99.77% 99.41% 97.96% 300.33% 107.05% 105.37% 107.92%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -15.01% -22.57% -11.72% -39.07% -48.41% -47.18% -42.20% -262.31% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -75.04% -61.72% -91.27% 80.89% -37.87% -27.66% -35.74% -185.89% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -2.16% -4.54% -2.45% -3.37% 12.91% 9.32% 15.11% 146.61% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -17.17% -27.11% -14.18% -42.43% -35.51% -37.86% -27.09% -115.70% -103.32% -103.46% -36.94%
Cash Return on Invested Capital (CROIC)		 -23.93% -12.97% -16.95% -177.86% -246.66% -132.03% -134.77% -279.10% -1,410.11% 0.00% 0.00%
Operating Return on Assets (OROA)		 -6.62% -12.34% -7.10% -14.71% -16.23% -19.11% -14.24% -20.46% -27.71% -29.37% -30.72%
Return on Assets (ROA)		 -7.43% -12.24% -7.34% -15.15% -16.60% -19.12% -14.09% -61.72% -29.86% -31.07% -33.17%
Return on Common Equity (ROCE)		 -17.17% -27.11% -14.18% -42.43% -35.51% -37.86% -27.09% -115.70% -103.32% -103.46% -36.94%
Return on Equity Simple (ROE_SIMPLE)		 -33.16% 0.00% -43.02% -47.67% -67.59% 0.00% -61.02% -224.28% -91.53% 0.00% -24.62%
Net Operating Profit after Tax (NOPAT)		 -11 -17 -8.88 -17 -19 -23 -18 -17 -19 -24 -23
NOPAT Margin		 -9.52% -17.06% -9.82% -21.78% -26.77% -32.79% -36.89% -45.31% -60.14% -85.69% -122.56%
Net Nonoperating Expense Percent (NNEP)		 60.03% 39.15% 79.55% -119.96% -10.54% -19.52% -6.46% -76.42% -8.18% -7.99% -6.50%
Return On Investment Capital (ROIC_SIMPLE)		 -1.96% -3.18% - - - -4.11% - - - -16.84% -
Cost of Revenue to Revenue		 20.63% 22.91% 23.02% 25.97% 25.76% 35.97% 21.43% 18.17% 15.76% 44.34% 0.00%
SG&A Expenses to Revenue		 51.71% 57.17% 55.93% 63.19% 65.93% 66.40% 76.54% 87.87% 95.64% 94.85% 119.88%
R&D to Revenue		 41.26% 44.29% 35.09% 41.95% 46.55% 44.48% 54.72% 58.70% 74.52% 111.46% 139.60%
Operating Expenses to Revenue		 92.98% 101.45% 91.01% 105.14% 112.48% 110.88% 131.26% 146.57% 170.16% 178.07% 275.09%
Earnings before Interest and Taxes (EBIT)		 -13 -24 -14 -24 -25 -36 -24 -25 -28 -34 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.59 -18 -7.29 -18 -19 -30 -21 -23 -27 -33 -33
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 9.47 8.80 8.02 7.04 5.03 5.53 4.50 12.52 6.46 5.06 4.06
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 112.65 44.37 10.92 8.65 5.54
Price to Revenue (P/Rev)		 5.82 5.89 6.06 6.10 5.27 7.38 8.36 8.50 9.52 9.33 13.16
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 9.14 8.32 7.63 6.75 4.97 5.19 4.50 17.68 85.88 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 5.85 5.94 6.10 6.14 5.29 7.49 8.36 8.29 8.14 7.36 9.61
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 193.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.32 1.37 1.33 1.34 1.31 1.23 1.14 3.89 0.00 0.00 0.00
Long-Term Debt to Equity		 1.32 1.37 1.33 1.34 1.31 1.23 1.14 3.89 0.00 0.00 0.00
Financial Leverage		 0.03 0.07 0.03 -0.04 -0.34 -0.34 -0.42 -0.79 -1.09 -1.19 -1.73
Leverage Ratio		 2.87 2.78 2.63 3.59 2.62 2.56 2.32 3.91 2.45 2.47 2.66
Compound Leverage Factor		 2.99 2.82 2.65 3.60 2.62 2.54 2.27 11.75 2.62 2.60 2.87
Debt to Total Capital		 56.95% 57.72% 57.01% 57.30% 56.67% 55.20% 53.21% 79.54% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 56.95% 57.72% 57.01% 57.30% 56.67% 55.20% 53.21% 79.54% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 43.05% 42.28% 42.99% 42.70% 43.33% 44.80% 46.79% 20.46% 100.00% 100.00% 100.00%
Debt to EBITDA		 -6.29 -5.04 -4.10 -3.47 -3.27 -3.06 -2.94 -2.64 0.00 0.00 0.00
Net Debt to EBITDA		 -0.19 -0.24 -0.18 -0.13 -0.04 -0.20 0.00 0.21 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -6.29 -5.04 -4.10 -3.47 -3.27 -3.06 -2.94 -2.64 0.00 0.00 0.00
Debt to NOPAT		 -5.77 -5.02 -4.58 -4.05 -4.04 -4.01 -3.95 -3.69 0.00 0.00 0.00
Net Debt to NOPAT		 -0.18 -0.24 -0.20 -0.15 -0.05 -0.26 0.00 0.29 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -5.77 -5.02 -4.58 -4.05 -4.04 -4.01 -3.95 -3.69 0.00 0.00 0.00
Altman Z-Score		 2.54 2.19 2.14 1.70 1.19 1.53 1.46 1.01 1.52 0.81 1.13
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.22 3.10 3.34 3.28 3.68 4.45 5.20 6.59 3.53 2.94 4.19
Quick Ratio		 2.93 2.83 3.05 3.02 3.38 4.07 4.74 6.28 3.21 2.71 3.92
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 11 15 -203 -248 -301 -303 -86 -59 -56 -156
Operating Cash Flow to CapEx		 -4,782.93% -25,340.00% 2,201.11% -488.19% 117,015.38% 0.00% 0.00% -25,486.76% -45,790.24% -14,161.16% -136,973.68%
Free Cash Flow to Firm to Interest Expense		 -4.11 3.17 4.10 -56.94 -69.34 -84.55 -84.70 -1.62 -13.92 -12.74 -39.18
Operating Cash Flow to Interest Expense		 -0.55 -1.42 1.11 -1.07 4.25 -4.66 -5.10 -0.33 -4.43 -7.86 -6.55
Operating Cash Flow Less CapEx to Interest Expense		 -0.56 -1.42 1.06 -1.28 4.25 -4.66 -5.10 -0.33 -4.44 -7.92 -6.56
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.57 0.51 0.47 0.48 0.45 0.37 0.29 0.31 0.31 0.24 0.17
Accounts Receivable Turnover		 5.03 4.61 5.28 5.52 5.62 4.05 4.51 4.70 5.89 5.65 6.25
Inventory Turnover		 3.94 3.65 1.68 1.81 0.91 3.37 1.51 1.81 1.22 3.50 0.00
Fixed Asset Turnover		 471.41 365.19 307.18 268.81 325.11 230.09 182.97 136.37 107.91 81.33 56.38
Accounts Payable Turnover		 6.29 7.41 4.36 2.16 1.15 5.84 2.46 1.05 0.87 1.39 0.00
Days Sales Outstanding (DSO)		 72.59 79.23 69.17 66.10 64.90 90.05 80.92 77.73 62.00 64.56 58.41
Days Inventory Outstanding (DIO)		 92.53 99.95 217.17 201.13 400.74 108.16 241.96 201.72 300.31 104.39 0.00
Days Payable Outstanding (DPO)		 58.06 49.25 83.78 168.76 318.43 62.49 148.50 349.26 417.23 263.35 0.00
Cash Conversion Cycle (CCC)		 107.06 129.93 202.56 98.47 147.21 135.72 174.38 -69.80 -54.93 -94.40 58.41
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 243 240 245 241 239 269 269 54 9.08 -9.68 -16
Invested Capital Turnover		 1.58 1.32 1.19 1.79 1.81 1.44 1.14 5.79 -8.75 -3.02 -0.64
Increase / (Decrease) in Invested Capital		 4.16 -28 -24 186 230 278 285 69 40 32 133
Enterprise Value (EV)		 2,218 2,000 1,874 1,623 1,185 1,396 1,210 960 780 567 503
Market Capitalization		 2,208 1,985 1,861 1,611 1,181 1,376 1,210 984 912 719 688
Book Value per Share		 $4.76 $4.70 $4.86 $4.86 $4.99 $5.33 $7.03 $2.07 $3.72 $3.85 $5.17
Tangible Book Value per Share		 ($0.22) ($0.50) ($0.50) ($0.70) ($0.49) ($0.09) $0.28 $0.58 $2.20 $2.25 $3.79
Total Capital		 542 534 540 536 541 555 575 384 141 142 169
Total Debt		 309 308 308 307 307 306 306 306 0.00 0.00 0.00
Total Long-Term Debt		 309 308 308 307 307 306 306 306 0.00 0.00 0.00
Net Debt		 9.50 15 13 12 3.99 20 -0.01 -24 -132 -152 -185
Capital Expenditures (CapEx)		 0.04 0.02 0.18 0.78 0.01 0.00 0.00 0.07 0.04 0.24 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 5.14 -15 -14 -23 -19 14 7.89 -4.64 -8.58 -26 -21
Debt-free Net Working Capital (DFNWC)		 283 266 271 256 284 300 314 325 123 125 164
Net Working Capital (NWC)		 283 266 271 256 284 300 314 325 123 125 164
Net Nonoperating Expense (NNE)		 4.05 6.83 5.36 7.68 6.75 13 5.98 57 11 13 13
Net Nonoperating Obligations (NNO)		 9.50 15 13 12 3.99 20 -0.01 -24 -132 -152 -185
Total Depreciation and Amortization (D&A)		 6.49 6.47 6.48 6.26 6.08 5.89 3.07 1.64 1.34 1.89 0.51
Debt-free, Cash-free Net Working Capital to Revenue		 1.36% -4.31% -4.56% -8.74% -8.61% 7.59% 5.45% -4.01% -8.96% -34.03% -40.52%
Debt-free Net Working Capital to Revenue		 74.68% 79.03% 88.22% 96.65% 126.59% 161.22% 216.90% 280.97% 128.95% 162.85% 313.91%
Net Working Capital to Revenue		 74.68% 79.03% 88.22% 96.65% 126.59% 161.22% 216.90% 280.97% 128.95% 162.85% 313.91%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.30) ($0.49) ($0.30) ($0.52) ($0.54) ($0.69) ($0.57) ($1.94) ($0.80) ($0.98) ($1.02)
Adjusted Weighted Average Basic Shares Outstanding		 48.89M 47.52M 47.78M 47.24M 46.93M 40.89M 41.10M 38.11M 37.68M 33.84M 34.93M
Adjusted Diluted Earnings per Share		 ($0.30) ($0.49) ($0.30) ($0.52) ($0.54) ($0.69) ($0.57) ($1.94) ($0.80) ($0.99) ($1.02)
Adjusted Weighted Average Diluted Shares Outstanding		 48.89M 47.52M 47.78M 47.24M 46.93M 40.89M 41.10M 38.11M 37.68M 33.98M 34.93M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.53M 49.01M 48.00M 47.71M 47.13M 47.00M 46.61M 38.30M 38.03M 37.95M 36.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -17 -8.88 -17 -19 -23 -18 -17 -19 -24 -23
Normalized NOPAT Margin		 -9.52% -17.06% -9.82% -21.78% -26.77% -32.79% -36.89% -45.31% -60.14% -85.69% -122.56%
Pre Tax Income Margin		 -12.23% -24.51% -15.37% -30.82% -35.62% -50.94% -48.90% -196.61% -94.72% -130.05% -190.06%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3.64 -6.70 -3.84 -6.70 -6.91 -10.00 -6.67 -0.46 -6.59 -7.90 -8.33
NOPAT to Interest Expense		 -2.96 -4.74 -2.48 -4.75 -5.18 -6.40 -4.93 -0.32 -4.48 -5.49 -5.80
EBIT Less CapEx to Interest Expense		 -3.65 -6.71 -3.89 -6.92 -6.91 -10.00 -6.67 -0.47 -6.60 -7.96 -8.33
NOPAT Less CapEx to Interest Expense		 -2.97 -4.74 -2.53 -4.97 -5.18 -6.40 -4.93 -0.32 -4.49 -5.54 -5.80
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.17% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Mirum Pharmaceuticals' Financials

When does Mirum Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Mirum Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Mirum Pharmaceuticals' net income changed over the last 5 years?

Mirum Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$87.94 million in 2024, rising from -$52.55 million in 2019. The previous period was -$163.42 million in 2023. Check out Mirum Pharmaceuticals' forecast to explore projected trends and price targets.

What is Mirum Pharmaceuticals's operating income?
Mirum Pharmaceuticals's total operating income in 2024 was -$87.61 million, based on the following breakdown:
  • Total Gross Profit: $255.25 million
  • Total Operating Expenses: $342.85 million
How has Mirum Pharmaceuticals revenue changed over the last 5 years?

Over the last 5 years, Mirum Pharmaceuticals' total revenue changed from $0.00 in 2019 to $336.89 million in 2024, a change of 33,688,800,000.0%.

How much debt does Mirum Pharmaceuticals have?

Mirum Pharmaceuticals' total liabilities were at $445.11 million at the end of 2024, a 11.9% increase from 2023, and a 18,075.3% increase since 2018.

How much cash does Mirum Pharmaceuticals have?

In the past 6 years, Mirum Pharmaceuticals' cash and equivalents has ranged from $11.97 million in 2019 to $286.33 million in 2023, and is currently $222.50 million as of their latest financial filing in 2024.

How has Mirum Pharmaceuticals' book value per share changed over the last 5 years?

Over the last 5 years, Mirum Pharmaceuticals' book value per share changed from 5.67 in 2019 to 4.70 in 2024, a change of -17.1%.


Related Companies

This page (NASDAQ:MIRM) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored